Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

Summary

This study is an interventional, prospective, multicentric, single-arm, open label, phase Ib clinical trial. This study will be carried out in patients diagnosed of metastatic or locally advanced unresectable triple negative breast cancer with activation of ERK and/or CDK4/6 in which the following will be assesed: the overall response rate, the aggregation of antitumor effect depending on the different kinome profiles and the safety profile to the combination of palbociclib and binimetinib.

Timeline

Start

2020-11-18

Primary completion

2023-12-14

Completion

2023-12-14

Publications

• Manso L, Sanchez-Bayona R, Guerra JA, Cortes-Salgado A, Cejalvo JM, Garcia-Saenz JA, Morales S, Gonzalez-Cortijo L, Mouron S, Bueno MJ, Garma LD, Quintela-Fandino M. A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer. Cancer Res Commun. 2025 Sep 1;5(9):1728-1737. doi: 10.1158/2767-9764.CRC-25-0428.

Drugs

Indications